Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter W Marks

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
JAMA|August 9, 2020
Unwavering Regulatory Safeguards for COVID-19 VaccinesAnand Shah, Peter W Marks, Stephen M Hahn
The New England Journal of Medicine|December 14, 2016
Clarifying Stem-Cell Therapy's Benefits and RisksPeter W Marks, Celia M Witten, Robert M Califf
JAMA|December 9, 2022
Urgent Need for Next-Generation COVID-19 VaccinesPeter W Marks, Philip A Gruppuso, Eli Y Adashi
The Journal of Infectious Diseases|March 11, 2016
Maintaining a Safe Blood Supply in an Era of Emerging PathogensPeter W Marks, Jay S Epstein, Luciana L Borio
The New England Journal of Medicine|March 27, 2023
End of a Declared Public Health Emergency - Implications for U.S. Emergency Use AuthorizationsPeter W Marks, Hilary D Marston, Lindsey R Baden
Archives of Internal Medicine|July 28, 2004
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhageSophia Koo, Nils Kucher, Paul L Nguyen, et al.
Vaccine|April 4, 2022
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 yearsPatrick R Funk, Osman N Yogurtcu, Richard A Forshee, et al.
Vaccine: X|June 16, 2023
Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 yearsOsman N Yogurtcu, Patrick R Funk, Richard A Forshee, et al.
Transfusion|May 26, 2004
Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 daysC Robert Valeri, Gina Ragno, Peter W Marks, et al.
Cancer|June 16, 2004
Gemcitabine-associated thrombotic microangiopathyBenjamin D Humphreys, Jeff P Sharman, Joel M Henderson, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
JAMA|August 9, 2020
Unwavering Regulatory Safeguards for COVID-19 VaccinesAnand Shah, Peter W Marks, Stephen M Hahn
The New England Journal of Medicine|December 14, 2016
Clarifying Stem-Cell Therapy's Benefits and RisksPeter W Marks, Celia M Witten, Robert M Califf
JAMA|December 9, 2022
Urgent Need for Next-Generation COVID-19 VaccinesPeter W Marks, Philip A Gruppuso, Eli Y Adashi
The Journal of Infectious Diseases|March 11, 2016
Maintaining a Safe Blood Supply in an Era of Emerging PathogensPeter W Marks, Jay S Epstein, Luciana L Borio
The New England Journal of Medicine|March 27, 2023
End of a Declared Public Health Emergency - Implications for U.S. Emergency Use AuthorizationsPeter W Marks, Hilary D Marston, Lindsey R Baden
Archives of Internal Medicine|July 28, 2004
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhageSophia Koo, Nils Kucher, Paul L Nguyen, et al.
Vaccine|April 4, 2022
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 yearsPatrick R Funk, Osman N Yogurtcu, Richard A Forshee, et al.
Vaccine: X|June 16, 2023
Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 yearsOsman N Yogurtcu, Patrick R Funk, Richard A Forshee, et al.
Transfusion|May 26, 2004
Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 daysC Robert Valeri, Gina Ragno, Peter W Marks, et al.
Cancer|June 16, 2004
Gemcitabine-associated thrombotic microangiopathyBenjamin D Humphreys, Jeff P Sharman, Joel M Henderson, et al.
Pageof 4